| Message: | Product Name Eptifibatide;
Sequence? Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2
Cas No. 148031-34-9
Molecular Formula C35H49N11O9S2
Molecular Weight 832.4
Appearance White slightly yellwish powder
Specific Rotation[20/D] -75.0～-95.0°（C=1，1%HAc）
Amino Acids composition ± 10%
Peptide Purity (By HPLC) ≥98% by area integration
Related Substance (By HPLC) Total Impurities (%)≤2.0%? Largest Single Impurity (%)≤ 1.0%
Water Content (Karl Fischer) ≤8.0%
Peptide Content(N determination) ≥80%
Acetate Content ≤15%
IR spectrum in accordance
Brief introduction:
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).
It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Indications
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
|
my account
